630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Salvatore Grisanti, Vivek Subbiah, Eric Baudin, Gedske Daugaard, Alfredo Berruti, Jennifer Martinez, Camilo Jimenez, Harm Haak, Jerome Kervevan, Lucie Aubergeon, Chloé Ventujol, Christophe Bonny, Laurent Chene, Joao Gamelas Magalhaes, CWillemien Menke-vander Houven van Oordt, Martin Fassnacht, Jaume Capdevila, Christelle de la Fouchardière, Dan Granberg, Matthias Kroiss, Hélène Toussaint, Camille Belyn, Jean-Michel Paillarse
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMJ Publishing Group 2023-11-01
Rangatū:	Journal for ImmunoTherapy of Cancer
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite